The impact of long-lasting microbial larvicides in reducing malaria transmission and clinical malaria incidence: study protocol for a cluster randomized controlled trial. by Zhou, Guofa et al.
STUDY PROTOCOL Open Access
The impact of long-lasting microbial
larvicides in reducing malaria transmission
and clinical malaria incidence: study
protocol for a cluster randomized
controlled trial
Guofa Zhou1, Virginia Wiseman2,3, Harrysone E. Atieli4,5, Ming-Chieh Lee1, Andrew K. Githeko4 and Guiyun Yan1*
Abstract
Background: The massive scale-up of insecticide-treated nets (ITNs) and indoor residual spraying (IRS) has led to a
substantial increase in malaria vector insecticide resistance as well as in increased outdoor transmission, both of which
hamper the effectiveness and efficiency of ITN and IRS. Long-lasting microbial larvicide can be a cost-effective new
supplemental intervention tool for malaria control.
Methods/design: We will implement the long-lasting microbial larvicide intervention in 28 clusters in two counties
in western Kenya. We will test FourStar controlled release larvicide (6 % by weight Bacillus thuringiensis israelensis and
1 % Bacillus sphaerius) by applying FourStar controlled release granule formulation, 90-day briquettes, and 180-day
briquettes in different habitat types. The primary endpoint is clinical malaria incidence rate and the secondary endpoint
is malaria vector abundance and transmission intensity. The intervention will be conducted as a two-step approach.
First, we will conduct a four-cluster trial (two clusters per county, with one of the two clusters randomly assigned to
the intervention arm) to optimize the larvicide application scheme. Second, we will conduct an open-label, cluster-
randomized trial to evaluate the effectiveness and cost-effectiveness of the larvicide. Fourteen clusters in each county
will be assigned to intervention (treatment) or no intervention (control) by a block randomization on the basis of
clinical malaria incidence, vector density, and human population size per site. We will treat each treatment cluster
with larvicide for three rounds at 4-month intervals, followed by no treatment for the following 8 months. Next, we
will switch the control and treatment sites. The former control sites will receive three rounds of larvicide treatment at
appropriate time intervals, and former treatment sites will receive no larvicide. We will monitor indoor and outdoor
vector abundance using CO2-baited CDC light traps equipped with collection bottle rotators. Clinical malaria data will
be aggregated from government-run malaria treatment centers.
Discussion: Since current first-line vector intervention methods do not target outdoor transmission and will select
for higher insecticide resistance, new methods beyond bed nets and IRS should be considered. Long-lasting microbial
larviciding represents a promising new tool that can target both indoor and outdoor transmission and alleviate the
problem of pyrethroid resistance. It also has the potential to diminish costs by reducing larvicide reapplications. If
successful, it could revolutionize malaria vector control in Africa, just as long-lasting bed nets have done.
Trial registration: U.S. National Institute of Health, study ID NCT02392832. Registered on 3 February 2015.
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Background
In the past decade, the massive scale-up of insecticide-
treated bed nets (ITNs) and indoor residual spraying
(IRS), together with the use of artemisinin-based
combination treatments, have led to major changes in
malaria epidemiology and vector biology. Overall malaria
prevalence and incidence have been greatly reduced
worldwide [1]. But the reductions in malaria have not
been achieved uniformly; some sites have experienced
continued reductions in both clinical malaria and overall
parasite prevalence [2–6], while other sites showed
stability or resurgence in malaria despite high coverage
of ITNs and IRS [7–12]. Persistence and resurgence of
vector populations continues to be an important issue
for malaria control and elimination [12–16]. More
importantly, extensive use of ITNs and IRS has created
intensive selection pressures for malaria vector insecti-
cide resistance as well as for potential outdoor transmis-
sion, which appears to be limiting the success of ITNs
and IRS. For example, in Africa, where malaria is most
prevalent and pyrethroid-impregnated ITNs have been
used for more than a decade, there is ample evidence of
the emergence and spread of pyrethroid resistance in
Anopheles gambiae s.s., the major African malaria vector,
as well as in An. arabiensis and An. funestus s.l. [17–20].
Both the prevalence of An. gambiae s.s. resistance to
pyrethroids and DDT and the frequency of knock-down
resistance (kdr) have reached alarming levels throughout
Africa from 2010–2012 [18]. Unfortunately, pyrethroids
are the only class of insecticides that the World Health
Organization (WHO) recommends for the treatment of
ITNs [21]. Furthermore, a number of recent studies have
documented a shift in the biting behavior of An. gam-
biae s.s. and An. funestus, from biting exclusively
indoors at night to biting both indoors and outdoors
during early evening and morning hours when people
are active but not protected by IRS or ITNs, or to biting
indoors but resting outdoors [22–24]. Apart from these
intraspecific changes in biting behavior, shifts in vector
species composition, i.e., from the previously predomin-
ant indoor-biting An. gambiae s.s. to the concurrently
predominant species An. arabiensis, which prefers to
bite and rest outdoors in some parts of Africa, can also
increase outdoor transmission [25–28]. Because IRS and
ITNs have little impact on outdoor-resting and outdoor-
and early-biting vectors, outdoor transmission repre-
sents one of the most important challenges in malaria
control. New interventions are urgently needed to
augment current public health measures and reduce
outdoor transmission [29].
Larval control has historically been very successful and
is widely used for mosquito control in many parts of the
developed world [30–33], but is not commonly used in
Africa. Field evaluation of anopheline mosquitoes in
Africa found that larviciding was effective in killing
anopheline larvae and reducing adult malaria vector
abundance in various sites [34–39]. Microbial larvicides
are effective in controlling malaria vectors, and they can
be used on a large scale in combination with ongoing
ITN and IRS programs [35, 38, 40]. However, conven-
tional larvicide formulations are associated with high
material and operational costs due to the need for
frequent habitat re-treatment, i.e., weekly re-treatment,
as well as logistical issues in the field [34–36, 40, 41].
Recently, an improved slow-release larvicide formulation
was field-tested for controlling Anopheles mosquitoes,
yielding an effective duration of approximately 4 weeks
[42]. Considering the monthly reapplication interval, this
still may not be a cost-effective product for large-scale
application. The new US EPA-approved long-lasting
formulation, FourStar Microbial Briquets (Central Life
Sciences, Sag Harbor, NY, USA), is potentially effective
for up to 6 months (http://www.centralmosquitocon-
trol.com/all-products/fourstar/fourstar-briquet-180), and
preliminary data suggest that it is effective in malaria
mosquito control [GZ, unpublished data]. Field-testing is
needed to determine the efficacy and cost-effectiveness
of this long-lasting larvicide.
The central objective of this study is to determine the
effectiveness and cost-effectiveness of long-lasting mi-
crobial larviciding (LLML) on the incidence of clinical
malaria and the reduction of transmission intensity. The
hypothesis is that adding LLML to ongoing ITN and IRS
programs will lead to significant reductions in both
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indoor and outdoor malaria transmission and malaria
incidence as well as cost savings. This paper describes a
protocol for evaluating the impact of LLML in redu-
cing malaria vector populations and clinical malaria
incidence.
Methods/design
Hypothesis, larvicides, and endpoint outcomes
Hypothesis
The addition of LLML to ongoing ITN and IRS pro-
grams will lead to significant reductions in both in-
door and outdoor malaria transmission and malaria
incidence.
Objective
The central objective of this trial is to determine the
impact and cost-effectiveness of LLML in reducing
malaria transmission and clinical malaria incidence in
Africa.
Trial design
This is an open-label, cluster-randomized controlled
trial with two arms and a baseline period which allows
for crossover.
Microbial larvicide formulations
We will test the FourStar LLML manufactured by
Central Life Sciences. The active ingredients are Bacillus
thuringiensis israelensis (Bti) (6 % by weight) and Bacillus
sphaerius (Bs) (1 % by weight). We will treat temporary,
semipermanent, and permanent habitats with controlled-
release granule formulation, 90-day briquettes, and 180-
day briquets, respectively. Application dosage will follow
the recommendation of the manufacturer: 10 lbs per acre
of water surface for the granule formulation, and one
briquette per 100 ft2 of water surface for the briquette
formulations, regardless of water depth. Re-treatment will
occur at a frequency of 4 to 5 months.
Primary and secondary endpoint
The primary endpoint is the clinical malaria incidence
rate. The secondary endpoint is the malaria vector
abundance and transmission intensity. A clinical malaria
case is defined as an individual with fever (axillary
temperature of 37.5 °C or higher) and other related
symptoms such as chills, severe malaise, headache, or
vomiting in the presence of a Plasmodium-positive
blood smear. The clinical malaria incidence rate is calcu-
lated as the number of clinical malaria episodes divided
by the total person time (person years) at risk based on
demographic surveys. Malaria vector abundance is mea-
sured as the total density of malaria vector mosquitoes
(An. gambiae s.s., An. arabiensis, An. funestus, and other
new species capable of transmitting malaria) collected
indoors and outdoors by CO2-baited light traps. Malaria
transmission intensity is measured as the sum of the
indoor and outdoor entomological inoculation rates
(EIRs).
Study area
We will conduct our study in 28 randomly selected clus-
ters in the highland localities (1400 m to 1600 m altitude)
of Kakamega and Vihiga counties, western Kenya (34°34’
to 34°50’E, 0°00’ to 0°12’N) (Fig. 1). A cluster typically
consists of an area of approximately 4 km2 in size and
comprises 400–700 households and about 2000–3000
residents. The catchment population of the study area, in-
cluding intervention clusters, control clusters, and buffer
zones, is estimated as 250,000 according to 2010 census
data.
Local residents are predominantly farmers and depend
upon farming, cattle and goat herding for subsistence.
Malaria transmission is seasonal, with two peaks in vec-
tor abundance reflecting the bimodal rainfall pattern: a
major peak between April and June and a minor peak
between October and November [43]. Most malaria is
caused by Plasmodium falciparum [12]. The main mal-
aria vectors in the area are An. gambiae s.s., An. ara-
biensis, and An. funestus s.l. [43, 44]. Malaria vector
density was high in the early 2000s, decreased substan-
tially during 2006–2008 after the first round of mass dis-
tribution of ITNs in 2006, and has gradually increased
since 2008 [12]. Pyrethrum spray collections (PSC) of
indoor-resting Anopheles were about 1.0 females/house/
night in 2014 compared to 0.1 females/house/night in
2007 [12, 45]. Cross-sectional community-level surveys
in May 2011 indicated that parasite prevalence averaged
11.8 % in the general population (all ages) but varied
between localities from 3.3 % to 25.4 % [44]. In school
children aged 6–13 years, surveys in 2012 found an aver-
age parasite prevalence of 27.2 %, which varied from
18.8 to 35.4 % among villages [45, 46]. Active case
surveillance through bi-weekly home visits in May 2011
indicated an average annual clinical malaria incidence
rate of 31.4 cases per 1000 people in the general popula-
tion, varying from 28.9 to 36.2 between villages [47].
Ownership of ITNs (mainly long-lasting insecticidal
nets) ranged from 78.3 to 84.2 % in 2013 [48]. There
have been several attempts in the past 10 years to con-
trol malaria vectors in the study area using conventional
formulations of Bti/Bs (i.e., through weekly re-treatment
of larval habitats) and IRS [35, 39, 44, 49]. The last
community-wide mass distribution of ITNs was under-
taken by the Division of Malaria Control (DOMC) of
Kenya in 2014. Currently there is no mass distribution
of ITNs or IRS and no larviciding in the proposed
study area.
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Demographic survey and cluster definition
For purposes of planning and conducting an evaluation
of the intervention, we will subdivide the field area into
villages (clusters), which is the smallest administrative
unit in Kenya. Using villages as clusters has advantages
over random sampling. First, the clinical records in
health centers or hospitals in Kenya generally include
the name of the village and sublocation (the next-
highest administrative level); therefore, clinical malaria
cases can be traced back to the village level. Second,
villages have been conveniently used as intervention/
control clusters in previous trials [15, 50].
Our field team will conduct the demographic surveys
before the start of the intervention. Each team will be
provided with a printed overview map (Figs. 1 and 2)
and a handheld Google Nexus 7 tablet. A surveillance
team, comprising a field technician, a reporter, and a
local guide, will visit every compound to explain the
study procedures, tally inhabitants, and collect informa-
tion on house characteristics. If the head of the compound
agrees to participate, we will record the geographical
coordinates of the main house of the compound and
compound codes will be written in permanent marker on
the front wall next to the door. We will record the genders
and ages of all compound members on questionnaire
forms using the on-site Google Nexus 7, which will
update the database in real time together with the GPS
coordinates of the surveyed compound. We will map the
locations of all compounds using ArcGIS 10 (Fig. 2).
Demographic surveillance will be done in year 1, 6–12
months prior to intervention (Fig. 3).
We will draw village boundaries based on the demo-
graphic surveys and confirm it with the field teams and
the database manager. If a village is too small (i.e., fewer
than 100 households, or fewer than 500 inhabitants, or
with an area less than 1 km2), we will combine the
Fig. 1 Map of study area and distribution of clinics and hospitals with catchment areas overlapping the study area
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village with a neighboring village to form one cluster.
Total and age- and gender-specific populations will be
aggregated at the cluster level.
Clinical malaria records collection
Clinical malaria records will be collected from 8 to
12 months prior to intervention, to calculate baseline
incidence rate at each cluster for cluster randomization,
through to 8 to 12 months after all interventions (Fig. 3).
We will collect information on clinical malaria cases
retrospectively from all government-run hospitals, health
care centers, and clinics located either within the study
area itself or within catchment areas overlapping the
study area. We will obtain clinical data from the
Fig. 2 A section of study area showing the distribution of households and clusters for field evaluation of long-lasting microbial larvicides. The area
with a unique color represents a cluster
Fig. 3 Timeline for the schedules of enrollment, interventions, and assessments
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treatment centers through the malaria control office of
Kakamega and Vihiga counties, Kenya. We will also
collect patient- and treatment-related information, in-
cluding age, gender, date of diagnosis, parasite species,
village of patient (or sublocation if village is missing),
and prescriptions given. All personal identifiers will be
excluded from this study. A clinical malaria case is
defined as an individual with fever (axillary temperature
of 37.5 °C or higher) and other related symptoms such
as chills, severe malaise, headache, or vomiting in the
presence of a Plasmodium-positive blood smear [47].
The clinical malaria incidence rate is calculated as the
number of clinical malaria episodes divided by the total
person time (person years) at risk based on demographic
surveys [47]. We will also collect the aggregated monthly
diarrhea data at each site along with clinical malaria
records from local health clinics and hospitals. We will
not conduct prospective passive surveillance, active
home visits, or cross-sectional blood surveys.
We will calculate the clinical malaria incidence rate
separately for each cluster, different study period and
different age group (i.e., under 5, 5–14, over 14 years).
We will include all clinical malaria cases in our study,
including cases diagnosed during the four study periods
(Fig. 3): (A) preintervention period: baseline clinical
malaria records started at least 8–12 months prior to the
application of long-lasting microbial larvicides till inter-
vention, (B) intervention period: all clinical records dur-
ing the intervention period, (C) the 8-month wash-out
period, and (D) postintervention period: clinical malaria
records till 8–12 months after the last round of larvicide
application.
Ethical and conflict of interest statement
Permission to use microbial larvicides for malaria vector
control has been obtained from the Pest Control
Products Board of Kenya. Ethical clearance has been
approved by the Scientific and Ethical Unit of the Kenya
Medical Research Institute (KEMRI). As described, ag-
gregated clinical data will be obtained from the treat-
ment centers through the malaria control offices of
Kakamega and Vihiga counties, Kenya. According to US
Department of Health and Human Services Code of
Federal Regulations 45 CFR 46.101(b) part 4 (Categories
of Exempt Human Subjects Research), these data are in
the category of exempt human subjects research, which
involves the study of existing data, documents, or
records, with no collection of subject-level information.
Informed consent will be obtained from each partici-
pant. All investigative team members in the United
States, Kenya, and Australia have no financial conflict
of interest with the larvicide manufacturer, Central
Life Sciences.
Malaria vector population monitoring
We will conduct baseline malaria vector surveillance at
least 4 months prior to any application of LLMLs (Fig. 3).
We will conduct malaria vector population surveillance
on a monthly basis continuously till at least 8 months
after the last round of larvicide application (Fig. 3). We
will monitor both indoor- and outdoor-biting mosquito
abundance using CO2-baited Centers for Disease Con-
trol (CDC) light traps equipped with collection bottle
rotators (Model 1512, John W. Hock Co., Gainesville,
FL, USA). The collection bottle rotator, which has eight
separate plastic collection bottles, will be programmed
to collect active mosquitoes at 2-h intervals between
16:00–08:00. We will place two traps within each sam-
pling compound: one inside the living room, the other
outside the house 5 m away. We will conduct a total of
64 trap-nights of vector sampling per cluster per month.
This will provide an estimation precision of 0.2 mosqui-
toes using the previously determined standard deviation
[51]. Species of collected mosquitoes will be identified
and blood-feeding status will be recorded. We will test
for P. falciparum sporozoite infection and blood meal
source using an enzyme-linked immunosorbent assay
(ELISA) on all specimens [52, 53]. For each house where
the vector population was sampled, we will record the
number of sleeping persons at each house on the same
day as the vector survey. We will calculate sporozoite
rate and EIR for each cluster. EIRs will be calculated as
(the number of Anopheles per person) × (the average
number of persons bitten by one Anopheles in 1 day) × (
sporozoite rate), and standardized to a monthly basis.
The trapping method will allow for comparison of
indoor- and outdoor-biting mosquito abundance and
determination of nightly biting activity patterns. We will
calculate indoor and outdoor transmission intensities
separately assuming that all mosquitoes collected from a
compound had their blood meal from the same house-
hold. We will calculate EIR for the four study periods as
describe above: (A) preintervention period: baseline
vector surveillance started at least 6 months prior to the
application of long-lasting microbial larvicides till inter-
vention, (B) intervention period, (C) the 8-month wash-
out period, and (D) postintervention period: vector
surveillance continued till 8 months after the last round
of larvicide application.
To determine whether new malaria vector species are
present in the study sites, we will sequence the riboso-
mal second internal transcribed spacer (ITS2) and mito-
chondrial CO1 gene in anopheline specimens that are
not amplified by the recombinant deoxyribonucleic acid
polymerase chain reaction (rDNA-PCR) method, and we
will conduct phylogenetic analysis to determine whether
the new species found by Stevenson et al. are also
present in the study sites [54].
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Intervention design
We will conduct the intervention using a two-step ap-
proach. First, we will conduct a small-scale four-cluster
trial to optimize the time, duration, and quantity of
LLML application. Second, we will conduct a cluster-
randomized trial to test the effectiveness and cost-
effectiveness of LLML. The design has two parallel arms,
i.e., control and intervention, and allows for baseline
survey without intervention and crossover (Fig. 3).
Small-scale entomological evaluation
We will select four clusters, two in each county, for an
entomological evaluation of the optimal larvicide appli-
cation scheme (Fig. 3). We will randomly select two
clusters, one in each county, treated with larvicides
(intervention) and the other two sites will serve as
controls (no intervention). We will treat temporary habi-
tats with FourStar controlled release granule formula-
tion, which maintains effectiveness through wet and dry
periods for up to 1 month. We will treat semipermanent
habitats with FourStar 90-day briquettes and permanent
habitats with FourStar 180-day briquettes. Application
dosage will follow the recommendation of the manufac-
turer, Central Life Sciences: 10 lbs per acre of water sur-
face for the granule formulation, and one briquette per
100 ft2 of water surface for the briquette formulations,
regardless of water depth. We will re-treat the habitats
every 4 to 5 months. On a weekly basis in the treatment
and control sites, we will use aerial samplers to deter-
mine habitat pupal productivity, and use standard dip-
pers to determine larval abundance. This will allow for
determination of habitat productivity with a tolerable
error of 0.5 mosquitoes, based on the standard deviation
identified in previous studies [55]. We will monitor
indoor and outdoor vector abundance using 64 trap-
nights per cluster per month. This sample size will allow
detection of a difference in average vector abundance of
0.12 mosquitoes with 80 % statistical power and 0.05
type-I error. We will use ELISA methods to determine
Anopheles mosquitoes’ sporozoite infection and blood-
feeding host preference [43].
We will analyze the data immediately after the small-
scale trial (Fig. 3) using analysis of variance (ANOVA)
with repeated measures and appropriate transformation
to determine the effects of habitat larviciding on mos-
quito abundance and transmission intensity [56]. The
percentage reduction in malaria transmission intensity
will be calculated [57].
Randomization
We will assign fourteen clusters each in the two counties
to intervention (treatment) or no intervention (control)
by a block randomization method on the basis of clinical
malaria incidence, vector density, and human population
size per site. Year 1 will focus on preparing the study
sites and working with clinics and hospitals to help them
improve their routine malaria surveillance (Fig. 3). In
year 2, we will conduct preliminary surveys on all 28
sites to determine (1) clinical malaria incidence, (2)
vector density, (3) geographic information system (GIS)
coordinates of larval habitats, and (4) human population
size. Human population size for each cluster, stratified
into three age groups (under 5 years, 5–15 years and
over 15 years) will be ascertained from our existing data.
We will obtain age-group level aggregated morbidity
data (the number of clinical malaria cases per age group,
without identifiers) from local hospitals and clinics
where the sampled residents seek treatment. These
clinical data are reported to the Ministry of Health of
Kenya and hence are publicly available. We will deter-
mine vector abundance using CO2-baited CDC light
traps for 16 trap-nights per cluster per month in each of
the indoor and outdoor environments.
Using these data, each cluster will be allocated to ei-
ther treatment or control through randomization using
the following procedures. First, each of the four parame-
ters listed above will be standardized with the highest
cluster as 1. Second, we will assign the highest weight
for clinical malaria cases (weight = 5), the lowest weight
for human population size (0.5), and intermediate
weights for expected vector density (2) and larval habi-
tats (2), following the method of Corbel et al. [58]. For
each cluster a rank score will be computed as the sum
of weighted clinical malaria incidence, vector density,
habitat abundance, and human population size. Finally,
the 14 clusters within each county will be sequentially
numbered according to their rank scores and sorted into
seven blocks of two clusters having successive rank
scores. We expect the two clusters within each block to
have similar risk characteristics for clinical malaria, vec-
tor abundance, larval habitats, and human population
size. In each block, the ranks of the two clusters are put
into two sealed envelopes, one cluster will be randomly
allocated to treatment and another to control, using
computer-generated random numbers (0 – control, 1 –
intervention).
Intervention strategy and regime
After the larvicide application optimization and study
cluster randomization, we will treat each treatment clus-
ter with LLML at the time interval of 4 or 5 months
(Fig. 3). The first treatment will be conducted in
February-March about 1 month before the beginning of
the long rainy season which usually starts in April. After
three treatments, we will perform no treatments for the
next 8 months. This will provide useful data on the
dynamics of action of the LLML and the waning efficacy
of LLML over time. These data will be important in
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analyzing cost-effectiveness to help optimize the timing
of re-treatments. After 8 months, a total washout of the
LLMLs will be assumed to have taken place. Next, we
will perform a crossover and switch of the control and
treatment clusters. Former control clusters will receive
three rounds of LLML treatment at appropriate time
intervals, and the former treatment clusters will receive
no LLMLs. This strategy will minimize ascertainment
biases that might be attributed to care-seeking behaviors
of the population or to malaria detection and reporting
by malaria treatment clinics. We will test LLMLs manu-
factured by Central Life Sciences. The larvicide applica-
tion regime is as follows: temporary, semipermanent,
and permanent habitats will be treated with FourStar
controlled release granule formulation, 90-day bri-
quettes, and 180-day briquettes, respectively. Application
dosage will follow the recommendation of the manufac-
turer: 10 lbs per acre of water surface for the granule
formulation, and 100 ft2 water surface per briquette.
We will conduct monthly vector surveys throughout
the study period (Fig. 3) to determine indoor- and
outdoor-biting vector abundance, using the same sample
size of 64 trap-nights per cluster per month, and sporo-
zoite infection and mosquito blood meal analysis will be
conducted on all collected specimens. To confirm larvi-
ciding efficacy, we will examine larval abundance, age
structure, and pupal productivity on a monthly basis in
100 randomly selected larval habitats each from treat-
ment and control sites using our GIS maps and data on
sites where LLML was applied.
Sample size justification
Sample size was calculated based on 2010 and 2011 ac-
tive case surveillance results from Iguhu and Emutete
areas [47]. Then the number of clusters required and the
number of individuals required for each cluster were
calculated following the methods developed by Hayes
and Bennett based on cluster-randomized trials assum-
ing equal population for each cluster [59]. The observed
malaria incidence rate was 52.7 cases per 1000 people
year in 2011. We calculated the numbers of clusters
(matched-pairs) and individuals required for epidemio-
logical (clinical malaria) assessment of the long-lasting
larvicide treatments to detect a 50 % protective efficacy
conferred by the treatment compared with the reference
group (no treatment), with a power of 80 %, significance
level of 5 % and the coefficient of variation of true
proportions between clusters within each treatment was
assumed to be 0.15. The estimated number of clusters
(matched-pairs) for the intervention will be five and the
required number of individuals for each matched-pair
will be 1196; assuming a design effect of 0.25 and 20 %
of subjects lost to follow-up. The estimated number of
clusters (matched-pairs) for the intervention will be
seven and the required number of individuals for each of
the matched-pairs will be fewer than 2000. The 28 clus-
ters proposed in the randomized cluster study will detect
50 % malaria incidence reduction with 99.9 % power and
30 % incidence reduction with 85.3 % power. This is
based on the current malaria incidence rate in the study
sites (52 clinic cases per 1000 population year) and a
two-tailed alpha with a human population size of 2000
per cluster (Table 1). If the malaria incidence is 50 %
lower than the current value, the design will still detect
50 % incidence reduction with 99.7 % power and 40 %
reduction with 95.2 % power (Table 1).
Data analysis
We will monitor primary and secondary endpoint out-
comes throughout the 5-year study period (Fig. 3); data
analysis will be conducted in year 5. The difference in
clinical malaria incidence between treatment and control
groups will be compared using Poisson multivariate
regression models with intervention, age, and calendar
time as covariates, using a generalized estimating equa-
tions (GEE) approach. GEE is necessary since incidence
will be modeled monthly as a temporally-correlated
repeated measure using grouped data. Intervention will
be a time-varying covariate since the treatment crosses
over after three intervention rounds. Since there is no
intervention in the 8 months during the washout period,
interval censoring will be performed to exclude the
second 4 months of data during this period. The odds
ratio and the 95 % confidence interval for clinical mal-
aria rates between treatment and control groups will be
calculated. Difference in vector density and EIR will be
analyzed using a negative binomial regression model and
the GEE approach. In all these analyses, clusters will be
indicated as intervention and control, calendar time will
be categorized into: pre intervention, intervention, post-
intervention (4 months), washout (4 months), crossover
intervention, postintervention (4 months), and noninter-
vention, and months since intervention (for both first
intervention and crossover) will also be included as an
independent variable. These variables will allow for com-
parison between intervention and control clusters based
on baseline observations, e.g., relative reduction in vec-
tor density, and allow for evaluation of cumulative effect,
Table 1 Calculated power (%) to detect various levels of
incidence reduction under three incidence scenarios
Annual incidence rate
(cases/1000 population)
Malaria incidence reduction
50 % 40 % 30 % 20 %
Observed in the site: 52 99.9 98.7 85.3 48.6
Low-incidence value: 26 99.7 95.2 74.4 38.9
High-incidence value: 78 99.9 99.3 89.0 53.0
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e.g., the second round of treatment may produce added-
effect following first-round treatment [49, 60, 61].
Finally, for the economic evaluation, we will calculate
incremental cost-effectiveness ratios (ICERs) based on
the primary endpoint (clinical malaria cases prevented)
and on long-term health outcomes including malaria
deaths averted. Using the “ingredients approach” [62, 63],
costs will be classified according to: initial setup invest-
ment (e.g., capital for vehicles used in transporting
larvicides, GPS units for habitat mapping, storage space
and equipment, and traps for mosquito surveillance),
running costs (e.g., long-lasting larvicides, salary for
larvicide application staff, staff training, protective
clothes, gloves, fuel costs, and vehicle insurance), and
costs of program management and quality control (e.g.,
material procurement, project coordinator, and quality
controller). Cost data will be estimated from health
facility and Ministry of Health records, LLML manufac-
turers and financial accounts of the research project.
One-way and multi-way sensitivity analysis will be
undertaken to examine the implications of potential
changes in variables such as larvicide price and larvicid-
ing application frequency. ICERs will be reported from
both provider and societal perspectives for different
transmission intensity scenarios.
Discussion
Larval control and environmental management have
played very important roles in malaria elimination in the
United States and Europe, where today larval control
using biological larvicides is the primary vector control
method [64–66]. Larvicides target mosquito larvae,
representing a major advantage over adult control, in
which changes in biting and resting behaviors can lead
adult mosquitoes to evade control activities. In addition,
microbial larvicides from bacteria Bti and Bs have differ-
ent modes of action than pyrethroid insecticides; there-
fore, microbial larvicides do not aggravate pyrethroid
resistance. Microbial larvicides are also considered safe
for non-target organisms and human health [67]. Fur-
thermore, larval control does not conflict with but rather
complements the front-line ITN and IRS malaria control
programs [66]. Larval control may now be timelier than
ever, since pyrethroid resistance and outdoor malaria
transmission are increasing in Africa.
However, there are some potential limitations of larvi-
ciding as it is practiced today. Although there are three
formulations of long-lasting larvicide available for use in
different habitat types (i.e., temporary habitats, semiper-
manent habitats, and permanent habitats), the classifica-
tion of habitats is primarily based on the longevity of the
aquatic period and productivity of the habitat. The lon-
gevity of the aquatic period may be visually identified;
however, the productivity of a habitat may change over
time [68–71]. Canopy cover in the habitat, such as
grasses in the water, may affect the spread of Bti/Bs
[Zhou, personal observations]. Furthermore, heavy rain-
fall may wash away Bti/Bs and create new habitat; there-
fore, additional Bti/Bs may need to be applied at an
unplanned time after the rain.
There are also limitations for the design. The inci-
dence of clinical malaria is essential for the evaluation of
intervention success. However, as pointed out by previ-
ous studies [47, 72], crude health facility records are not
always a reliable source of such information and may
in fact under estimate the true clinical incidence rate
[47, 72]. However, as long as clinical malaria was diag-
nosed the same way across all health care facilities, com-
parison between intervention and control groups is
justified. EIR is a good measure of reduction in transmis-
sion since larval control reduces overall vector population
density and EIR is measured based on vector population
density. Additional indicators, such as clinical incidence
through active case surveillance, can be a more accurate
estimate of incidence, and parasite prevalence through
cross-sectional surveillance may be helpful. However, as
per restrictions imposed by the funding policy, direct
measures of human subjects are restricted.
Despite very high bed net coverage, malaria incidence
in many African sites is resurging after a short-time re-
duction when ITN and IRS scale-up was initially rolled
out. This malaria resurgence is caused primarily by in-
creases in insecticide resistance and outdoor transmis-
sion. New cost-effective methods beyond bed nets and
IRS are urgently needed. Long-lasting microbial larvi-
ciding represents a promising new tool that can target
both indoor and outdoor transmission and alleviate
the problem of pyrethroid resistance. Comprehensive
evaluation of potentially cost-effective LLML will pro-
vide critically needed data for determining whether
LLML can be used as a supplemental malaria control
tool to further reduce malaria incidence in Africa.
Trial status
This trial is still in its early stages. Retrospective collec-
tion of clinical malaria in the study area is underway.
Larvicide importation permission has been approved
from the Pest Control Products Board of Kenya. No
recruiting or larvicide application has been started.
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